secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001193125-25-002872
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis reports FY2024 revenue ~$84.6M (+15% YoY), above guidance; cash ~$185M
--------------------------------------------------------------------------------

- Full year 2024 revenue of ~$84.6M, up 15% from $73.5M in 2023, above guidance range of $83-84M.
- Pharma/enterprise/other revenue grew 20% to ~$77.2M despite Natera revenue declining 20% to ~$25.4M.
- Q4 revenue of ~$16.8M (down 15% YoY); delivered 1,441 molecular tests, up 52% from Q3.
- Cash, cash equivalents, and short-term investments of ~$185.0M, including $50M strategic investment from Merck; path to cash flow break-even.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525002872/0001193125-25-002872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525002872/d900005d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-002872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer